The present invention relates to a process of preparation of a biomaterial comprising the steps of: a) Preparing a solution comprising at least one protein having a solubility in water superior or equal to about 10 mg/mL and at least one salt having solubility in water superior or equal to about 500 mg/mL, b) Evaporating the solution obtained in step a) as is, as a foam obtained by foaming the solution obtained in step a), or as a mixture thereof, at a temperature comprised of from 4 to 50° C. in atmospheric pressure or at lower temperatures under vacuum or at a pressure lower than atmospheric pressure, until the formation of two non-miscible phases or until obtaining a substantially dry solid, thereby obtaining a biomaterial.

The present invention also relates to a biomaterial obtainable by the process, and to the use of the biomaterial as a support for in vitro tissue engineering and/or for in vitro cell culture and in vitro expansion and/or as an implantable medical device, or as a drug.

The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein of human serum albumin and human growth hormone; the concentration of the fusion protein is 10-100 mg/mL; the concentration of sucrose is 10-150 mg/mL; the concentration of a nonionic surfactant is 0.15-10 mg/mL; the concentration of a preservative is 0.5-12 mg/mL; the concentration of a buffer is 1-30 mM; and the pH is 5.0-8.0.

Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

Described and provided herein are novel antibodies for Claudin 18.2. Also described and provided are pharmaceutical compositions of the antibodies and methods of use for the treatment of cancer.

The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.

The present invention relates to conjugation-competent albumins and albumin-related polypeptides, and their conjugates with at least one moiety, and to polynucleotides encoding them.

The present invention includes compositions and methods for treating stroke in sickle cell anemia (SCA) patients. In certain embodiments, the patient is administered certain ENPP1- or ENNP3-containing polypeptides, mutants, or mutant fragments thereof.

The present invention includes compositions and methods for treating stroke in sickle cell anemia (SCA) patients. In certain embodiments, the patient is administered certain ENPP1- or ENNP3-containing polypeptides, mutants, or mutant fragments thereof.

Disclosed herein are genetically modified plants expressing multiple animal milk proteins. Further disclosed are vectors for expressing in a plant and parts thereof, multiple mammalian milk proteins; genetically modified and or gene-edited plants having at least one cell expressing and producing at least two recombinant mammalian milk proteins wherein expression may be in a seed, bean, grain, fruit, nut, legume, leaf, stem, root, or portion thereof, the recombinant protein being produced by the plant cell; and a method of producing a food, medicament, cosmetic or blocking composition from the genetically modified or gene-edited plant. Reduction or elimination of seed storage proteins in a cell or cells wherein the milk proteins are expressed, or reduction of plant enzymes that can increase the content of oleic and/or stearic fatty acids and/or reduce the content of saturated fats in the plants or plant products are also disclosed.

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.